Prostatype Genomics raises SEK 12.5M via TO6 warrant exercise
Prostatype Genomics AB said 98.3% of its TO6 warrants were exercised at SEK 0.10, bringing in about SEK 12.5M before costs, with the remainder covered by underwriting. The company expects total shares to rise by 131,225,546, implying about 19% dilution.